Peptide Profile
Dalargin
Leu-enkephalin-Arg · YGGFLR · dalarginum
Dalargin (D-Ala2-Leu5-Arg6-enkephalin) is a synthetic hexapeptide opioid receptor agonist developed in the Soviet Union as a stable enkephalin analog, designed with D-amino acid substitution to resist enzymatic degradation, and…
- Routes
- subcutaneous, intravenous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Dalargin is
About Dalargin
Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Reduces gastric acid secretion, promotes mucosal blood flow, and inhibits ulcer formation via prostaglandin-mediated pathways.
Dalargin (D-Ala2-Leu5-Arg6-enkephalin) is a synthetic hexapeptide opioid receptor agonist developed in the Soviet Union as a stable enkephalin analog, designed with D-amino acid substitution to resist enzymatic degradation, and investigated for gastroprotective and analgesic properties in animal models and limited Russian clinical use. Dalargin binds mu and delta opioid receptors and is proposed to exert gastroprotective effects through opioid receptor-mediated suppression of gastric acid secretion, stimulation of mucosal prostaglandin synthesis, and promotion of epithelial repair, with additional central analgesic activity demonstrated in preclinical studies. Published evidence in Western PubMed-indexed journals is limited to animal studies demonstrating gastroprotective activity against NSAID-induced mucosal damage; the compound has been used in Russian clinical practice for peptic ulcer disease, but no randomized controlled trials meeting current methodological standards have been published in English-language indexed journals. Dalargin has no FDA approval and no regulatory approval in any Western jurisdiction; it is an obscure research compound whose evidence base is largely confined to Soviet-era and Russian-language literature, and its safety and efficacy profile in humans has not been validated by independent clinical investigation.
Dalargin Benefits & Research Areas
What the evidence says about Dalargin
Research Evidence
based on 1 study · dated evidence base — most recent 2009
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
1 source cited · 1 moderate
1 Animal
Gastroprotective effect of dalargin in gastropathy due to treatment with nonsteroid antiinflammatory drugs
Bulletin of Experimental Biology and Medicine · 2009
Research in rats with indomethacin-induced gastric injury found that dalargin significantly reduced the area of erosive and ulcerative lesions, normalized epithelial cell proliferation, and decreased oxidative stress markers in gastric tissue, demonstrating gastroprotective and mucosal repair activity via opioid receptor pathways.
Dalargin Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSDalargin
Frequently Asked Questions — Dalargin
Dalargin (D-Ala2-Leu5-Arg6-enkephalin) is a synthetic hexapeptide opioid receptor agonist developed in the Soviet Union as a stable enkephalin analog, designed with D-amino acid substitution to resist enzymatic degradation, and investigated for gastroprotective and analgesic properties in animal models and limited Russian clinical use. Dalargin binds mu and delta opioid receptors and is proposed to exert gastroprotective effects through opioid receptor-mediated suppression of gastric acid secretion, stimulation of mucosal prostaglandin synthesis, and promotion of epithelial repair, with additional central analgesic activity demonstrated in preclinical studies.
gastroprotection, GI repair, anti-ulcer, pain modulation.
Research on Dalargin primarily documents effects related to gastroprotection and GI repair and anti-ulcer and pain modulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For Dalargin, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research in rats with indomethacin-induced gastric injury found that dalargin significantly reduced the area of erosive and ulcerative lesions, normalized epithelial cell proliferation, and decreased oxidative stress markers in gastric tissue, demonstrating gastroprotective and mucosal repair activity via opioid receptor pathways.
How to get Dalargin
Where to buy Dalargin
Coverage expanding
No verified providers currently list Dalargin. Get notified when one does, or explore providers carrying similar peptides in the Recovery category.
Questions to ask your provider
Stay updated on verified Dalargin providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.